Nanotechnology in vaccine delivery

Peek, Laura J.; Middaugh, C. Russell; Berkland, Cory

doi:10.1016/j.addr.2007.05.017

Cited by 482 publications

(360 citation statements)

References 180 publications

(255 reference statements)

Supporting

Mentioning

342

Contrasting

Unclassified

Order By: Relevance

“…Therefore, they can be better engulfed by APCs and the antigens can be delivered more efficiently. [16] There are basically two possible ways to take advantage of MPs/NPs for immunization purposes. One way consists of 70 encapsulating the antigen inside liposomes [17,18] or inside organic biodegradable polymers, such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), [19][20][21][22][23][24] disulfide cross-linked polyacrylates, [25] or polysaccharides, such as pullulan [26] and chitosan.…”

Section: Introductionmentioning

confidence: 99%

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Parra

Abad‐Somovilla

Mercader

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their 25 properties makes CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, as a model analyte. An azoxystrobin derivative bearing a carboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was 30 covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based constructs were obtained using efficient, fast, and easy functionalization procedures based on microwave-assisted chemistry. New Zealand rabbits and BALB/c mice were immunized with BSA-AZc6 alone and with the four CNT-BSA-AZc6 constructs, both with and without Freund's adjuvant. The IgG-type antibody responses were assessed 35 in terms of the titer and affinity, paying special attention to the relationship between the immune response and the size and shape of the employed CNTs. Immunization with CNT-BSA-AZc6 resulted in enhanced titers and excellent affinities for azoxystrobin. More important, remarkable IgG responses were obtained even in the absence of an adjuvant, thus proving the self-adjuvanting capability of CNTs. Immunogens were able to produce strong anti-azoxystrobin immune responses 40 in rabbits even when administered at a BSA-AZc6 conjugate dose as low as 0.05 g. The short and thick CNT-BSA-AZc6 construct produced the best antibody response under all tested conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Parra

Abad‐Somovilla

Mercader

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…In recent years, nanotechnology has been widely applied to the study of new adjuvant formulations and vaccine delivery systems [1,29,30]. The ability of vaccines (or their delivery systems) to self-assemble in nanoscale was found to be important for inducing immune responses.…”

Section: Resultsmentioning

confidence: 99%

pH-triggered peptide self-assembly into fibrils: a potential peptide-based subunit vaccine delivery platform

Skwarczynski¹,

Kowapradit²,

Ziora³

et al. 2013

Bio Chem Comp

View full text Add to dashboard Cite

Background: Peptide-based subunit vaccines require strong adjuvants (immunostimulant) for therapeutic potency. There is strong demand for the discovery of new safe adjuvants and vaccine delivery systems that can be produced in a highly controlled manner. The pH dependent self-assembly of isopeptide derivatives into fibrils has been reported. Appropriately designed fibrils may have adjuvanting potency. Methods: Isopeptides conjugated to B-cell peptide epitopes (antigens) were synthesized. Properties of the resultant conjugates and their ability to undergo O-N intramolecular acyl migration reaction were analysed by HPLC, circular dichroism, and transmission electron microscopy. Results: The conjugates were converted to "parent" peptides via the pH-triggered O-N acyl migration reaction. The parent peptides aggregated into fibrils. The differences in conjugates composition resulted in different fibril morphology. Aggregation of produced peptides induced desired secondary conformation of antigens (peptide epitopes). Conclusions:The isopeptide approach presented herein may serve as a new self-adjuvanting delivery system for peptide-based vaccines. Such vaccines could be stable when stored in a non-aggregative form, and then converted on demand to the active form in pH-controlled manner. The use of a vaccine that is solely composed of endogenous components may reduce vaccine-associated side effects.

show abstract

“…DNA administration, which exploits host cellular processes for antigen expression,78, 79, 80 is the simplest approach that may be feasible. In addition to administration of naked DNA with electroporation, several biotechnology alternatives exist as DNA vaccine delivery methods, and new technologies continue to offer promise 81, 82, 83, 84. Another unresolved question is how best to deliver such a complex set of antigens.…”

Section: Immune Selection In Longitudinal Samples: Ontogeny Of Cd4bs mentioning

confidence: 99%

Polyvalent vaccine approaches to combat HIV‐1 diversity

Korber

Hraber

Wagh

et al. 2017

Immunological Reviews

View full text Add to dashboard Cite

SummaryA key unresolved challenge for developing an effective HIV‐1 vaccine is the discovery of strategies to elicit immune responses that are able to cross‐protect against a significant fraction of the diverse viruses that are circulating worldwide. Here, we summarize some of the immunological implications of HIV‐1 diversity, and outline the rationale behind several polyvalent vaccine design strategies that are currently under evaluation. Vaccine‐elicited T‐cell responses, which contribute to the control of HIV‐1 in natural infections, are currently being considered in both prevention and treatment settings. Approaches now in preclinical and human trials include full proteins in novel vectors, concatenated conserved protein regions, and polyvalent strategies that improve coverage of epitope diversity and enhance the cross‐reactivity of responses. While many barriers to vaccine induction of broadly neutralizing antibody (bNAb) responses remain, epitope diversification has emerged as both a challenge and an opportunity. Recent longitudinal studies have traced the emergence of bNAbs in HIV‐1 infection, inspiring novel approaches to recapitulate and accelerate the events that give rise to potent bNAb in vivo. In this review, we have selected two such lineage‐based design strategies to illustrate how such in‐depth analysis can offer conceptual improvements that may bring us closer to an effective vaccine.

show abstract

Nanotechnology in vaccine delivery

Cited by 482 publications

References 180 publications

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

pH-triggered peptide self-assembly into fibrils: a potential peptide-based subunit vaccine delivery platform

Polyvalent vaccine approaches to combat HIV‐1 diversity

Contact Info

Product

Resources

About